NEW YORK, September 8, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.

-- Centene Corp. Research Reports On September 2, 2014, Centene Corp. (Centene) announced that the Company is planning to build a new claims processing center in Ferguson, Missouri, which will result in creation of 150 to 200 full-time jobs with numerous benefits, including extensive health care, dental and vision insurance. Centene informed that the new facility will process claims from its Missouri based Home State Health Plan and overflow from its other health plans across the country. Further, the Company will start accepting applications for the new claims processing center jobs before the end of 2014. In addition, the Company has authorized an expedited timeline for completion of this project. Meanwhile, the Company is looking for a temporary site for training and development. Michael Neidorff, Chairman and CEO, Centene, said, "The new Centene service center complex will include employee development and training, an on-site daycare, full service cafeteria and an auditorium for educational advancement." The full research reports on Centene are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/CNC/report.pdf

-- Mallinckrodt PLC Research Reports

On September 3, 2014, Mallinckrodt PLC (Mallinckrodt) reported the data from a Human Abuse Liability (HAL) study for MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen. The Company informed that in the study, both intact and crushed MNK-155 showed lower subjective abuse-related effects than an immediate-release hydrocodone bitartrate/acetaminophen formulation (a generic form of Vicodin(R)). Intact and crushed MNK-155 demonstrated statistically significant (p <0.001) lower measures of drug liking, drug high and good drug effects compared with comparable doses of intact immediate-release hydrocodone bitartrate/acetaminophen when measured at the peak drug effect (Emax). The full research reports on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/MNK/report.pdf

--

Infinity Pharmaceuticals Inc. Research Reports

On September 3, 2014, Infinity Pharmaceuticals Inc. (Infinity) announced that the Company has entered into a global collaboration with AbbVie Inc. (AbbVie) for developing and commercializing duvelisib (IPI-145), Infinity's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for treating cancer patients. According to the terms of the agreement, the Company will receive $275 million as upfront payment and is eligible to receive up to $530 million in additional payments upon achievement of development, regulatory and commercial milestones, including up to $405 million for the achievement of milestones through the first commercial sale of duvelisib. Further, in U.S., both companies will jointly commercialize duvelisib and will share profits equally, while outside U.S., AbbVie will be responsible for the conduct and funding of commercialization of duvelisib, and Infinity is eligible to receive tiered royalties on net product sales, in the range of 23.5% to 30.5%. The full research reports on Infinity are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/INFI/report.pdf

--

Celgene Corporation Research Reports

Celgene Corporation (Celgene) posted on the Events and Presentation section of its official website that the Company will participate in the upcoming Morgan Stanley Global Healthcare Conference on September 9, 2014 at 12:55 p.m. ET in New York. The full research reports on Celgene are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/CELG/report.pdf

--

UnitedHealth Group Inc. Research Reports

On August 28, 2014, UnitedHealth Group Inc. (UnitedHealth) reported the expansion of its partnership with Nebraska 4-H named Eat4-Health that helps in tackling obesity by promoting healthy eating and active lifestyles among youth and families. The Company is giving a grant of $24,000 to University of Nebraska Cooperative Extension, which administers 4-H programs, to support youth healthy-living programs. The Company informed that the grant will be used to purchase pedal-powered blender bikes which will be use in events in which which young people can create their own healthy smoothies through exercise. The grant will also support community events and programs this summer through spring 2015 in which youth and families can learn about easy ways to promote healthy lifestyles. Kathy Mallatt, President, UnitedHealthcare Community Plan of Nebraska, said, "UnitedHealthcare is grateful for the opportunity to continue our work with New York 4-H to help educate young people about healthy lifestyles and exercise in their daily lives." The full research reports on UnitedHealth are available to download free of charge at:

http://www.analystsreview.com/Sep-08-2014/UNH/report.pdf

--

About Analysts Review

We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review